Table 2 Ranibizumab Treatment and Outcomes Before Switch to Intravitreal Aflibercept

Delay between diagnosis of nAMD and first injection of ranibizumab, months

0.5 (1.2)

Number of ranibizumab injections

4.8 (1.9)

Duration of ranibizumab treatment, months

4.9 (2.8)

BCVA before any treatment (including ranibizumab), ETDRS letters

64.0 (15.6)

BCVA at baseline (switch to IVT-AFL), ETDRS letters

66.2 (12.1)

 Change in BCVA from before the start of any treatment (including ranibizumab) and baseline (switch to IVT-AFL)

2.2 (12.0)

 P value

0.046